ECSP10010158A - Derivados de piridina. - Google Patents

Derivados de piridina.

Info

Publication number
ECSP10010158A
ECSP10010158A EC2010010158A ECSP10010158A ECSP10010158A EC SP10010158 A ECSP10010158 A EC SP10010158A EC 2010010158 A EC2010010158 A EC 2010010158A EC SP10010158 A ECSP10010158 A EC SP10010158A EC SP10010158 A ECSP10010158 A EC SP10010158A
Authority
EC
Ecuador
Prior art keywords
piridine
derivatives
nephropathy
neuropathy
obesity
Prior art date
Application number
EC2010010158A
Other languages
English (en)
Inventor
Johannes Gleitz
Norbert Beier
Lars Thore Burgdorf
Christine Charon
Daniel Cravo
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP10010158A publication Critical patent/ECSP10010158A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Nuevos compuestos heterocíclicos de la fórmula I en donde R1, R2, R3, R4 y D tienen los significados indicados en la reivindicación 1,son activadores de la glucoquinasa y se pueden usar para la prevención y/o el tratamiento de diabetes de tipo 1 y 2, obesidad, neuropatía y/o nefropatía.
EC2010010158A 2007-10-09 2010-05-05 Derivados de piridina. ECSP10010158A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07019691 2007-10-09
EP08001168 2008-01-23

Publications (1)

Publication Number Publication Date
ECSP10010158A true ECSP10010158A (es) 2010-06-29

Family

ID=39870670

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010158A ECSP10010158A (es) 2007-10-09 2010-05-05 Derivados de piridina.

Country Status (22)

Country Link
US (1) US8420642B2 (es)
EP (1) EP2195312B1 (es)
JP (1) JP5567481B2 (es)
KR (1) KR20100090250A (es)
CN (1) CN101821264A (es)
AR (1) AR068748A1 (es)
AU (1) AU2008310097B2 (es)
BR (1) BRPI0818658A2 (es)
CA (1) CA2701806A1 (es)
CY (1) CY1113767T1 (es)
DK (1) DK2195312T3 (es)
EA (1) EA201000561A1 (es)
EC (1) ECSP10010158A (es)
ES (1) ES2399469T3 (es)
HR (1) HRP20120948T1 (es)
IL (1) IL204746A0 (es)
MX (1) MX2010003759A (es)
NZ (1) NZ585236A (es)
PL (1) PL2195312T3 (es)
PT (1) PT2195312E (es)
SI (1) SI2195312T1 (es)
WO (1) WO2009046784A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2573087A1 (en) 2007-09-21 2013-03-27 Array Biopharma, Inc. Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JPWO2012121314A1 (ja) 2011-03-09 2014-07-17 第一三共株式会社 ジピリジルアミン誘導体
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104230892B (zh) * 2011-11-09 2016-12-07 福建海西新药创制有限公司 一组提高激酶活性的化合物及其应用
KR102032007B1 (ko) 2012-02-28 2019-10-14 아스텔라스세이야쿠 가부시키가이샤 질소 함유 방향족 헤테로환 화합물
WO2013138617A1 (en) 2012-03-16 2013-09-19 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
CN103664759A (zh) * 2013-12-06 2014-03-26 常熟市联创化学有限公司 一种3-羟基-2-硝基吡啶的制备方法
TWI703133B (zh) 2014-12-23 2020-09-01 美商艾克斯基製藥公司 ３,５-二胺基吡唑激酶抑制劑
EP3259256B1 (en) 2015-02-17 2022-03-09 Beijing Erai Therapeutics Co., Ltd. Compounds and methods for inducing browning of white adipose tissue
CN114716390A (zh) * 2015-04-07 2022-07-08 Ela制药有限公司 用于治疗和/或预防细胞或组织坏死的组合物和方法
WO2016164703A1 (en) * 2015-04-09 2016-10-13 Eisai R & D Management Co., Ltd. Fgfr4 inhibitors
WO2020051424A1 (en) 2018-09-07 2020-03-12 Pic Therapeutics Eif4e inhibitors and uses thereof
CN110568100B (zh) * 2019-09-12 2022-05-31 江西金水宝制药有限公司 一种米格列奈钙r-异构体的检测方法
TW202146393A (zh) 2020-03-03 2021-12-16 美商皮克醫療公司 Eif4e抑制劑及其用途
US20240116962A1 (en) * 2020-12-31 2024-04-11 Tsinghua University Pyridine-2-amine derivative and pharmaceutical composition and use thereof
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
CA3229560A1 (en) 2021-08-25 2023-03-02 Christopher L. Vandeusen Eif4e inhibitors and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE49198T1 (de) * 1984-05-12 1990-01-15 Fisons Plc Antiinflammatorische 1,n-diarylpyrazol-3-amine, deren zusammensetzungen und verfahren zu deren herstellung.
EP0267740A1 (en) 1986-11-06 1988-05-18 Schering Corporation Naphthyridine and pyridopyrazine compounds and pharmaceutical usage thereof
JPH07285962A (ja) 1994-04-20 1995-10-31 Nissan Chem Ind Ltd ピリジンカルボン酸アミド誘導体
US5856347A (en) 1994-11-29 1999-01-05 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
AU4515896A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
WO1996018616A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
AU779908B2 (en) 1999-09-10 2005-02-17 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2001269821A1 (en) 2000-06-15 2001-12-24 Barbara Chen Cycloalkyl alkanoic acids as integrin receptor antagonists
NZ522793A (en) * 2000-07-04 2005-02-25 Neurosearch As Aryl and heteroaryl diazabicycloalkanes, their preparation and use
AU2002213467A8 (en) 2000-10-11 2009-07-30 Chemocentryx Inc Modulation of ccr4 function
WO2002050071A1 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP1432706A2 (en) 2001-09-26 2004-06-30 Bayer Pharmaceuticals Corporation 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
EP1336607A1 (en) 2002-02-19 2003-08-20 Novo Nordisk A/S Amide derivatives as glucokinase activators
PL370989A1 (en) * 2001-12-21 2005-06-13 Novo Nordisk A/S Amide derivatives as gk activators
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
JP2006517234A (ja) 2003-02-10 2006-07-20 アムジエン・インコーポレーテツド バニロイド受容体リガンドおよび治療におけるこれらのリガンドの使用
US7432287B2 (en) * 2003-02-26 2008-10-07 Banyu Pharmeceutical Co., Ltd. Heteroarylcarbamoylbenzene derivative
WO2004103960A2 (en) 2003-05-16 2004-12-02 Ambit Biosciences Corporation Compounds and uses thereof
JP2007504229A (ja) * 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体−５のモジュレーターとしてのビピリジルアミン類およびエーテル類
WO2005040112A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
US7687502B2 (en) * 2004-03-23 2010-03-30 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
AU2005232753A1 (en) * 2004-04-13 2005-10-27 Astellas Pharma Inc. Polycylic thiazoles as potassium ion channel modulators
US20060019967A1 (en) 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
ES2377430T3 (es) 2004-09-02 2012-03-27 Genentech, Inc. Inhibidores piridílicos de la señalización de hedgehog
WO2006078621A2 (en) 2005-01-19 2006-07-27 Bristol-Myers Squibb Company 2-phenoxy-n- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
CA2600869A1 (en) 2005-03-18 2006-09-28 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr processing and uses thereof
AU2006241825A1 (en) 2005-04-28 2006-11-09 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine
UA92746C2 (en) * 2005-05-09 2010-12-10 Акилайон Фармасьютикалз, Инк. Thiazole compounds and methods of use
KR101346902B1 (ko) * 2005-07-09 2014-01-02 아스트라제네카 아베 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한헤테로아릴 벤즈아미드 유도체
US20090156644A1 (en) 2005-07-21 2009-06-18 Jacob Westman Use of thiazole derivatives and analogues in the treatment of cancer
CN101273023A (zh) 2005-08-02 2008-09-24 Irm责任有限公司 作为蛋白激酶抑制剂的5-取代的噻唑-2-基氨基化合物和组合物
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
NZ567858A (en) * 2005-11-01 2011-08-26 Array Biopharma Inc Pyridine compounds useful as Glucokinase activators
WO2007051846A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
CN101437512A (zh) * 2006-01-27 2009-05-20 阿雷生物药品公司 葡萄糖激酶活化剂
RU2457207C2 (ru) 2006-03-24 2012-07-27 Эррэй Биофарма Инк. Активаторы глюкокиназы
WO2008091770A1 (en) 2007-01-24 2008-07-31 Array Biopharma Inc. 2-aminopyridine derivatives as glucokinase activators
EP2134709A1 (en) 2007-03-09 2009-12-23 Vertex Pharmaceuticals, Inc. Aminopyridines useful as inhibitors of protein kinases
CA2681695A1 (en) 2007-03-23 2008-10-02 Array Biopharma Inc. 2-aminopyridine analogs as glucokinase activators
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer

Also Published As

Publication number Publication date
CA2701806A1 (en) 2009-04-16
AU2008310097A1 (en) 2009-04-16
IL204746A0 (en) 2010-11-30
PT2195312E (pt) 2013-02-20
EA201000561A1 (ru) 2010-10-29
WO2009046784A1 (en) 2009-04-16
AR068748A1 (es) 2009-12-02
AU2008310097B2 (en) 2013-05-16
SI2195312T1 (sl) 2013-01-31
EP2195312A1 (en) 2010-06-16
ES2399469T3 (es) 2013-04-01
NZ585236A (en) 2012-03-30
HRP20120948T1 (hr) 2012-12-31
EP2195312B1 (en) 2012-11-21
MX2010003759A (es) 2010-04-21
BRPI0818658A2 (pt) 2015-04-14
JP2010540667A (ja) 2010-12-24
DK2195312T3 (da) 2013-01-02
US8420642B2 (en) 2013-04-16
JP5567481B2 (ja) 2014-08-06
CY1113767T1 (el) 2016-07-27
KR20100090250A (ko) 2010-08-13
US20100216794A1 (en) 2010-08-26
PL2195312T3 (pl) 2013-04-30
CN101821264A (zh) 2010-09-01

Similar Documents

Publication Publication Date Title
ECSP10010158A (es) Derivados de piridina.
ECSP10010163A (es) Derivados de n-(pirazol-3-il)-benzamida
EA201001358A1 (ru) Активаторы глюкокиназы
CY1112919T1 (el) Παραγωγα β-αμινοξεων για τη θεραπευτικη αντιμετωπιση του διαβητη
CL2008001017A1 (es) Compuestos derivados de indol, activadores de glucoquinasa; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de diabetes u obesidad.
CL2008003847A1 (es) Compuestos derivados de 6-fenilpirazin-2-carboxamida y 6-fenilpirazin-2-carbotioamida, inhibidores de dgat-1; composicion farmaceutica; y su uso en el tratamiento de la diabetes mellitus y obesidad.
CY1112921T1 (el) Ενεργοποιητες γλυκοκινασης πυρρολιδινονης
DE502007004290D1 (de) Carbazol-derivate für organische elektrolumineszenzvorrichtungen
CO6270257A2 (es) Derivados de piridazinona
UY28005A1 (es) Indol -3-carboxamidas como activadores de glucoquinasa (gk)
CY1109322T1 (el) Παραγωγα προλινης και η χρηση τους ως αναστολεις διπεπτιδυλικης πεπτιδασης iv
EP2468725A4 (en) AROMATIC AMINE DERIVATIVES AND ORGANIC ELECTROLUMINESCENE ELEMENTS THEREWITH
CL2008000915A1 (es) Compuestos triciclicos moduladores de 11beta-hidroxiesteroidedeshidrogenasa tipo 1; y uso en el tratamiento, prevencion y/o profilaxis de enfermedades tales como sindrome metabolico, resistencia a la insulina, dislipidemia, hipertension y obesidad.
MX2008011123A (es) Benzotiazoles que tienen actividad de receptor h3 de histamina.
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
MX2009012708A (es) Derivados de piridazinona.
CL2008002871A1 (es) Compuestos derivados de oxadiazol-bencimidazol; composicion farmaceutica que los contiene y su uso como inhibidores de dgt1 para el tratamiento de la tolerancia deteriorada a la glucosa, diabetes tipo 2 y obesidad.
ECSP088164A (es) Derivados de heteroaril benzamida para uso como activadores de glk en el tratamiento de la diabetes
EA201001367A1 (ru) Производные карбоксамид-гетероарила для лечения диабета
CL2007002757A1 (es) Compuestos derivados de 1,2,4-triazina sustituida; composicion farmaceutica; y uso en el tratamiento o prevencion del reflujo gastroesofagico y ansiedad.
ATE514765T1 (de) Azeotropartige zusammensetzungen mit 1,1,1,2,3,3- hexafluor-3-methoxypropan und 1-brompropan
ATE478054T1 (de) Benzimidazolderivate
NI201000051A (es) Benzotiazoles como moduladores del receptor de grelina.
UY30033A1 (es) Uso de derivados heterociclicos benzo _fusionados de sulfamida para el tratamiento de la obesidad
TW200700358A (en) Organic compounds